Drug intelligence / Profile preview

clarithromycin + didanosine

Development stage
Phase 1
Lead developer
Taisho Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Clarithromycin + didanosine is a combination of two pharmaceutical agents, clarithromycin and didanosine. Clarithromycin is a *macrolide antibiotic*, acting by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, primarily used for treating and preventing *Mycobacterium avium complex (MAC)* and a range of other bacterial infections[2][4]. Didanosine is an *antiretroviral* nucleoside analog, specifically a nucleoside reverse transcriptase inhibitor (NRTI), used primarily in the treatment of HIV infection. This combination may be considered in patients, particularly those with HIV/AIDS, to treat or prevent opportunistic infections, especially MAC. However, evidence for routine clinical use of this exact combination for other purposes is limited. There is no unique brand combining these two agents directly for specific diseases. Each drug has a distinct mechanism of action, and there is potential for drug-drug interactions when co-administered.

02

Targets

Bacterial 50S ribosomal subunitHuman immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on clarithromycin + didanosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clarithromycin + didanosine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call